This clinical trial is focused on studying a condition known as Multiple System Atrophy (MSA), a rare neurological disorder that affects the body’s involuntary functions, such as blood pressure, breathing, and motor control. The trial will investigate the effects of a treatment called Lu AF82422, also known as Amlenetug, which is a type of protein designed to target specific proteins in the brain. This treatment is administered as a solution for infusion, meaning it is given directly into the bloodstream through a vein.

The purpose of the study is to evaluate how effective Lu AF82422 is in slowing down the progression of MSA. Participants in the trial will receive either the treatment or a placebo, which is a substance with no active medication. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo, to ensure unbiased results. The trial will also include an optional open-label extension, where all participants may have the opportunity to receive the actual treatment after the initial phase.

Throughout the study, participants will be monitored for changes in their condition over a period of time, with assessments taking place up to 72 weeks. These assessments will include various tests and evaluations to measure the impact of the treatment on the symptoms and progression of MSA. The trial aims to provide valuable insights into the potential benefits of Lu AF82422 for individuals living with this challenging condition.